Previous 10 | Next 10 |
Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company Lucid Diagnostics to launch major new multi-channel commercialization initiative for its EsoGuard Esophageal DNA Test Conference call to be held today at 8:30 AM EST ...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Conference call and live webcast was previously scheduled for 4:30 PM EST Lucid Diagnostics strategic advisor and medical diagnostics pioneer Stanley Lapidus to join call NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Compan...
Comstock Mining (LODE) +285% after buying stake in lithium-ion battery recycler.TDH Holdings (PETZ) +248%.Dogness (International) (DOGZ) +110%.Oncolytics Biotech (ONCY) +54%.ZW Data Action Technologies (CNET) +42%.China Xiangtai Food (PLIN) +41%.AirNet Technology (ANTE) +34%.Aqua Metals ...
NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that the first U.S. patient recently underwent suc...
Are These On Your Penny Stocks List? With so much momentum every day for penny stocks , traders are always looking for the most valuable short and long term prospects. Because the term penny stocks means any security under $5, there are plenty of choices. But, just because there are...
Palm Beach, FL – February 11, 2021 – Cardiovascular devices are the medical devices which are used to diagnosis and treat the heart diseases and other heart-related problems. These devices play essential role prevention and treatment of cardiovascular diseases. The cardi...
PAVmed has a suite of medical devices that could improve on the current standard of care in multiple areas. Based on the opportunity in esophageal cancer screening alone, the company looks substantially undervalued with a current market cap of just $135 million. As an added bonus,...
NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company will host a business update conferenc...
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct o...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...